Denali Capital shareholders approve merger with Longevity Biomedical; 4.44M shares redeemed

Semnur Pharmaceuticals, Inc.

Shareholders approved all proposals: Business Combination, Merger, Share Capital, Organizational Documents, Governance, and Incentive Plan.
Approximately 4,440,202 public shares redeemed from trust account after withdrawals, ahead of closing.
Adjornment proposal not needed as sufficient votes secured for all other proposals.
Company plans to close the Business Combination as detailed in the proxy statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.